Project 2 ? Biomarkers of lung cancer risk Project Summary / Abstract The US National Lung Cancer Screening Trial (NLST) demonstrated in 2011 that screening with computed tomography (CT) scans can reduce lung cancer mortality by 20%, but with important costs including a high false-detection rate of 95%. The study also indicated important differences in the benefit of screening in different participant groups as defined by their underlying risk of lung cancer, thus highlighting the urgent need to develop improved risk prediction models for identifying eligible subjects to screen. Biomarker studies of lung cancer have reported a wide range of markers that appear strongly indicative of an individual's underlying risk of developing a cancer that may be combined with information afforded by traditional questionnaire based risk factors, in particular history of tobacco exposure. We hypothesize that a comprehensive and extensively validated risk prediction model that incorporates risk-informative circulating biomarkers has the potential to substantially improve existing risk prediction models, and our pilot data on a limited set of risk biomarkers strongly supports this hypothesis. Our project will focus on systematically assessing a comprehensive panel of biomarkers of lung cancer risk that have been implicated in previous studies, and evaluate the extent to the extent to which they can improve risk prediction. This will be achieved by bringing together data from ongoing large-scale biomarker studies, and conducting a comprehensive de novo analysis of promising risk biomarkers within the Lung Cancer Cohort Consortium (LC3). We will evaluate a wide range of promising risk biomarkers implicated in lung cancer by us or other research groups, including miRNAs, metabolic, immune, and protein biomarkers, as well as epigenetic markers. The initial stage will involve assaying a panel of Promising risk biomarkers at a centralized laboratory for 850 case- control pairs from three prospective cohorts from the US, Europe and Asia, with subsequent large-scale validation of the most informative markers in another 16 prospective cohorts from the LC3 consortium, including 1,750 additional case-control pairs. The versatility of the individual LC3 cohorts will also allow us to thoroughly assess important US minorities, including African American and Hispanic subjects. All lung cancer cases that will be included were diagnosed within 5 years of blood collection. We expect that this will result in establishing a distinct panel of validated and informative risk biomarkers for use in lung cancer risk prediction models, which will be further validated in CT screening studies in collaboration with Project 3.
Project 2 ? Biomarkers of lung cancer risk Project narrative Extensive pilot data strongly supports the use of biomarkers in lung cancer risk prediction models. Within Project 2 we will systematically evaluate a comprehensive panel of promising risk biomarkers using pre- diagnostic blood samples. This will result in a selected panel of biomarkers of lung cancer risk that will be incorporated in risk prediction models, and used to identify those subjects most likely to benefit from CT- screening.
|Barfield, Richard; Shen, Jincheng; Just, Allan C et al. (2017) Testing for the indirect effect under the null for genome-wide mediation analyses. Genet Epidemiol 41:824-833|
|Patel, Chirag J; Kerr, Jacqueline; Thomas, Duncan C et al. (2017) Opportunities and Challenges for Environmental Exposure Assessment in Population-Based Studies. Cancer Epidemiol Biomarkers Prev 26:1370-1380|
|Gauderman, W James; Mukherjee, Bhramar; Aschard, Hugues et al. (2017) Update on the State of the Science for Analytical Methods for Gene-Environment Interactions. Am J Epidemiol 186:762-770|
|Qian, David C; Molfese, David L; Jin, Jennifer L et al. (2017) Genome-wide imaging association study implicates functional activity and glial homeostasis of the caudate in smoking addiction. BMC Genomics 18:740|
|McAllister, Kimberly; Mechanic, Leah E; Amos, Christopher et al. (2017) Current Challenges and New Opportunities for Gene-Environment Interaction Studies of Complex Diseases. Am J Epidemiol 186:753-761|